



RETEPLASE (RETAVASE)



Escambia County, Florida - ALS/BLS Medical Protocol

FOR CRITICAL CARE TRANSFERS ONLY

ACTIONS

Reteplase is a recombinant plasminogen activator, which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

INDICATIONS

Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for lysis of thrombi obstructing coronary arteries.

CONTRAINDICATIONS

1. Active internal bleeding.
2. History of cerebrovascular accident.
3. Recent (within two months) intracranial or intraspinal surgery or trauma.
4. Intracranial neoplasm, arteriovenous malformation, or aneurysm.
5. Known bleeding diathesis.
6. Severe uncontrolled hypertension.

PRECAUTIONS

Non-compressible arterial puncture must be avoided (eg. internal jugular and subclavian punctures). Arterial and venous punctures should be minimized.



Approved: 10/01/2011
Version: 3.1

Page 1 of 2

Approved by:


Charles Neal, D.O. Medical Director



RETEPLASE (RETAVASE)



Escambia County, Florida - ALS/BLS Medical Protocol

ADVERSE REACTIONS AND SIDE EFFECTS

Bleeding is the most common adverse reaction; either internal or external or both.

Other adverse reactions include: dysrhythmias, nausea/vomiting, hypotension, and fever.

Mild hypersensitivity may produce urticaria.

DOSAGE


Adult: NOT APPROVED FOR PRE-HOSPITAL USE



Approved: 10/01/2011
Version: 3.1

Page 2 of 2

Approved by:


Charles Neal, D.O. Medical Director